RxDoctor Payments Data

David Speizman, DO

Internal Medicine · Boynton Beach, FLNPI 1952356685

Payments from drug & device makers

$4,112in general payments, 2019–2025

Across 221 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$598
  • Amgen$395
  • GSK$312
  • Amarin Pharma, Inc.$302
  • Johnson & Johnson$272
  • AstraZeneca$246
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,02198%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,112 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$354,525
Medicare patients
618
Services billed
6,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$229,294
JardianceEmpagliflozin61$91,736
FarxigaDapagliflozin Propanediol64$84,828
OzempicSemaglutide55$70,614
XareltoRivaroxaban65$68,308
Tresiba Flextouch U-200Insulin Degludec44$40,722
RybelsusSemaglutide24$31,136
LinzessLinaclotide31$30,040
EntrestoSacubitril/Valsartan23$29,951
Tresiba Flextouch U-100Insulin Degludec31$27,247
JanuviaSitagliptin Phosphate23$27,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,787
MyrbetriqMirabegron24$24,075
TrulicityDulaglutide18$20,799
Repatha SureclickEvolocumab11$16,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$229,294206 claims
Novo NordiskOzempic, Rybelsus$598$101,75079 claims
Boehringer IngelheimJardiance$24$91,73661 claims
AstraZenecaFarxiga$246$84,82864 claims
Johnson & JohnsonXarelto$272$68,30865 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$312$53,32985 claims
AbbVieLinzess, Synthroid$115$33,21974 claims
NovartisEntresto$132$29,95123 claims
MerckJanuvia$68$27,10423 claims
Astellas Pharma US IncMyrbetriq$105$24,07524 claims
Lilly USA, LLCTrulicity$78$20,79918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →